QUOTE AND NEWS
Benzinga  May 9  Comment 
In a report published Thursday, Piper Jaffray analyst Brooks E. West downgraded the rating on Hansen Medical (NASDAQ: HNSN) from Overweight to Neutral, and lowered the price target from $3.00 to $1.50. In the report, West noted, “HNSN...
Benzinga  May 9  Comment 
Analysts at Goldman Sachs downgraded Tesla Motors (NASDAQ: TSLA) from “buy” to “neutral.” The target price for Tesla Motors has been raised from $45 to $61. Tesla Motors' shares closed at $55.79 yesterday. Analysts at Jefferies...
StreetInsider.com  May 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Guidance/Hansen+Medical%2C+Inc.+%28HNSN%29+Misses+Q1+EPS+by+13c%3B+Updates+Outlook/8318686.html for the full story.
Benzinga  Dec 12  Comment 
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced changes to its Board of Directors. These changes include the appointment of Michael Eagle, a current director, as Chairman of the Board and the...
StreetInsider.com  Nov 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Hansen+Medical%2C+Inc.+%28HNSN%29+Posts+Q3+Loss+of+14cShare/7854277.html for the full story.
StreetInsider.com  Oct 31  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hansen+Medical+%28HNSN%29%2C+Intuitive+Surgical+%28ISRG%29+Expand+Patent+Portfolio+Agreement/7829625.html for the full story.
StreetInsider.com  Oct 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hansen+Medical+%28HNSN%29+Announces+Exhibition+of+Magellan%22+Robotic+System/7778414.html for the full story.
Stock Blog Hub  Aug 26  Comment 
Hansen Medical (HNSN), a global developer and manufacturer of intravascular robotics, recently announced the expansion of its intellectual property portfolio on the back of 30 additional patents in the U.S. since January 2011. The company also...
StreetInsider.com  Aug 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hansen+Medical+%28HNSN%29+Awarded+Thirty+Additional+U.S.+Patents+in+Medical+Robotics/7677259.html for the full story.
StreetInsider.com  Aug 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Hansen+Medical%2C+Inc.+%28HNSN%29+Posts+Q2+Loss+of+19cShare/7642960.html for the full story.




 
TOP CONTRIBUTORS

Hansen Medical (Nasdaq: HNSN) manufactures catheters and other flexible robotics used in catheter-based interventional medical procedures. The company's main robotic catheter product is used to treat irregular heart rhythms; it is developing additional products that will be used in targeted treatment of vascular disease. The company also has agreements with Philips to license its technology for application in other medical fields.[1]

Products

The company's only product approved in both the US and Europe is the Sensei robotic catheter system used in the treatment of irregular heart rhythms. The system retails for approximately $545,000 and catheter units cost $1,600. The company's vascular system was recently approved for use in Europe but hasn't yet been approved by the FDA.

Business Growth

In 2010 the company generated revenues of $16.6 million, down 25% from the previous year. The company has not yet generated any net income, losing $37.9 million in 2010, however this was 47% less than the amount lost in 2009.[2] The company sold only 12 Sensei units in 2010 compared to 26 unites in 2009.

Trends and Forces

Growth Potential Due to High Volume of Catheter-Based Procedures

Physicians are continually finding new and innovative procedures that can be performed via catheter, however the basic technology for delivering the catheter to the targeted area hasn't seen much development. Hansen Medical's robotic system helps physicians guide catheters to the correct spot with greater control of the device. Atrial fibrillation, treated by the Sensei system, is the most common heart arrhythmia and tens of thousands of procedures are performed each year. Hansen Medical's future depends on the continued growth of catheter-based procedures and increased adoption of its devices. There are nearly two million vascular procedures done each year and the company's new vascular system product will be able to address at least a third of these procedures.[3]

Lower Device Pricing, Fewer Sales, and Reduced Healthcare Spending

From 2009 to 2010, the average selling price of Hansen Medical's Sensei system dropped by $16,000 and the total number of units sold fell from 26 to 12. Both domestic and international sales of Sensei units fell by more than 50%.[4] The reduction in both sales and selling price reflects a broader worldwide trend of governments trying to rein in runaway healthcare costs.

Competition

Hansen Medical faces stiff competition from many other companies that manufacture and sell medical devices used in catheter-based procedures for heart arrhythmias and vascular diseases.

  • Medtronic (MDT) is one of the largest manufacturers of medical devices and has an entire division dedicated to Cardiac and Vascular interventions.
  • St. Jude Medical (STJ) produces a range of devices that are used for treating various cardiovascular problems including arrhythmias.
  • Boston Scientific (BSX) is a highly diversified manufacturer of medical devices, however 42% of their net sales come from cardiovascular related products.
  • Edwards Lifesciences (EW) is solely focused on devices that are used in the treatment and management of cardiovascular disease.

References

  1. HNSN Q2 2011 10-Q, p. 22
  2. HNSN 2010 10-K, p. 75
  3. CE Mark Approvals May Offer Safer Alternative for Biotech Investors, SeekingAlpha, 4/25/11
  4. HNSN 2010 10-K, p. 83
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki